Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agile Therapeutics Inc (NQ: AGRX )

3.640 -0.060 (-1.62%)
Streaming Delayed Price Updated: 3:58 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agile Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 – What Is The Hype All About?
Women are itching for more birth control options that cater to their unique needs and preferences. While traditional forms of birth control – such as the pill and condoms – have been reliable options... 
Via Benzinga
The Overturning of Roe v. Wade Has Changed The Landscape Of Birth Control; Smaller Companies Are Now An Integral Part Of Care
The invention of birth control in the 1960s revolutionized women's health and their lives. In 2022, the contraceptive market was valued at $8.3 billion and it is projected to grow at a compound annual... 
Via Benzinga
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
From Agile Therapeutics, Inc.
Via GlobeNewswire
A Look Into Healthcare Sector Value Stocks
 
Via Benzinga
Agile Therapeutics: Q1 Earnings Insights
 
Via Benzinga
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Earnings Preview
 
Via Benzinga
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
Live Conference Call and Webcast at 4:30 p.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics: The CEO Of This Women's Healthcare Company That Recently Saw Revenue Growth Of 33% Speaks To Benzinga
Al Altomari, Chairman & CEO of Agile Therapeutics (NASDAQ: AGRX) was recently a guest on Benzinga’s All Access. 
Via Benzinga
Agile Therapeutics's Return On Capital Employed Insights
 
Via Benzinga
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
By Johnny Rice, Benzinga 
Via TheNewswire.com
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
National Instruments, Nutex Health And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
From Agile Therapeutics, Inc.
Via GlobeNewswire
Why Kalera Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Innovative Eyewear, Inc. (NASDAQ: LUCY) jumped 164% to $3.86 after the company announced it launched ChatGPT-enabled smart eyewear. 
Via Benzinga
Why Agile Therapeutics Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Gainers ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) shares rose 82.8% to $2.98 in pre-market trading. ZyVersa Therapeutics recently reported new employment inducement grants under Nasdaq Listing Rule... 
Via Benzinga
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023. 
Via Benzinga
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
Live Conference Call and Webcast at 4:30 p.m. ET 
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
From Agile Therapeutics, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! 
Via InvestorPlace
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
From Agile Therapeutics, Inc.
Via GlobeNewswire
Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
From Agile Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women 
Via News Direct
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Al Altomari, Chairman and CEO of Agile Therapeutics Inc (NASDAQ: AGRX), was recently interviewed by Benzinga. 
Via Benzinga
Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan
From Agile Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.